Literature DB >> 11012629

Tumour necrosis factor-alpha (TNF-alpha) enhances lymphocyte migration into rheumatoid synovial tissue transplanted into severe combined immunodeficient (SCID) mice.

S Wahid1, M C Blades, D De Lord, I Brown, G Blake, G Yanni, D O Haskard, G S Panayi, C Pitzalis.   

Abstract

Adhesion mechanisms play a major role in the recruitment of peripheral blood lymphocytes (PBL) which characteristically infiltrate rheumatoid arthritis (RA) synovium and other chronically inflamed tissues. Through a sequential series of complex integrated adhesion and signalling events, 'multistep model of migration', specific subsets of PBL are recruited into inflamed tissues. In this process both leucocyte receptors and microvascular endothelial (MVE) counter-receptors play a critical role. The MVE in particular, during an inflammatory state, is the target of various inflammatory mediators that cause the up-regulation of several cell adhesion molecules (CAM). One of the most important factors known to be a powerful inducer of MVE CAM is TNF-alpha. Conversely, blocking TNF-alpha causes a down-modulation of CAM expression. To test directly the capacity of TNF-alpha to induce cell migration into RA synovium we adapted a model in which synovial grafts were implanted into SCID mice subcutaneously. Using this model we demonstrate that: (i) transplants remain viable and become vascularized and fed by mouse subdermal vessels; (ii) the mouse vasculature connects to the transplant vasculature which maintains the ability to express human CAM; (iii) intragraft injections of TNF-alpha up-regulate the expression of human CAM, following the down-regulation which occurred 4 weeks post-transplantation; and (iv) the up-regulation of graft CAM is associated with increased human PBL migration into the transplants. This study provides direct evidence in vivo of the capacity of TNF-alpha to induce cell migration. In addition, it provides the experimental background for the optimal use of this model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012629      PMCID: PMC1905754          DOI: 10.1046/j.1365-2249.2000.01342.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells.

Authors:  J J Campbell; G Haraldsen; J Pan; J Rottman; S Qin; P Ponath; D P Andrew; R Warnke; N Ruffing; N Kassam; L Wu; E C Butcher
Journal:  Nature       Date:  1999-08-19       Impact factor: 49.962

Review 2.  New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis.

Authors:  F Breedveld
Journal:  Eur Cytokine Netw       Date:  1998-09       Impact factor: 2.737

Review 3.  Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?

Authors:  R O Williams
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Review: angiogenesis: implications for rheumatoid arthritis.

Authors:  A E Koch
Journal:  Arthritis Rheum       Date:  1998-06

Review 5.  Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.

Authors:  M Feldmann; M J Elliott; J N Woody; R N Maini
Journal:  Adv Immunol       Date:  1997       Impact factor: 3.543

Review 6.  How do lymphocytes know where to go: current concepts and enigmas of lymphocyte homing.

Authors:  M Salmi; S Jalkanen
Journal:  Adv Immunol       Date:  1997       Impact factor: 3.543

7.  Cytokine-inducible growth factor gene expression in human umbilical endothelial cells.

Authors:  Y Ko; G Totzke; I Gouni-Berthold; A Sachinidis; H Vetter
Journal:  Mol Cell Probes       Date:  1999-06       Impact factor: 2.365

Review 8.  Inhibitors of tumor necrosis factor for rheumatoid arthritis.

Authors:  L W Moreland
Journal:  J Rheumatol Suppl       Date:  1999-05

Review 9.  Taming TNF: strategies to restrain this proinflammatory cytokine.

Authors:  A Eigler; B Sinha; G Hartmann; S Endres
Journal:  Immunol Today       Date:  1997-10

10.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

Authors:  E M Paleolog; S Young; A C Stark; R V McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1998-07
View more
  10 in total

Review 1.  Trojan horses and guided missiles: targeted therapies in the war on arthritis.

Authors:  Mathieu Ferrari; Shimobi C Onuoha; Costantino Pitzalis
Journal:  Nat Rev Rheumatol       Date:  2015-03-03       Impact factor: 20.543

2.  Inflammation, immune reactivity, and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis.

Authors:  Laurie S Davis; Marian Sackler; Ruth I Brezinschek; Ellis Lightfoot; Jennifer L Bailey; Nancy Oppenheimer-Marks; Peter E Lipsky
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

3.  H-2g, a glucose analog of blood group H antigen, mediates monocyte recruitment in vitro and in vivo via IL-8/CXCL8.

Authors:  Bradley J Rabquer; Yong Hou; Jeffrey H Ruth; Wei Luo; Daniel T Eitzman; Alisa E Koch; Mohammad A Amin
Journal:  Open Access Rheumatol       Date:  2012-09-18

4.  In vivo multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy.

Authors:  Jonathan Noonan; Steven M Asiala; Gianluca Grassia; Neil MacRitchie; Kirsten Gracie; Jake Carson; Matthew Moores; Mark Girolami; Angela C Bradshaw; Tomasz J Guzik; Gavin R Meehan; Hannah E Scales; James M Brewer; Iain B McInnes; Naveed Sattar; Karen Faulds; Paul Garside; Duncan Graham; Pasquale Maffia
Journal:  Theranostics       Date:  2018-11-29       Impact factor: 11.556

Review 5.  Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies.

Authors:  Katina Schinnerling; Carlos Rosas; Lilian Soto; Ranjeny Thomas; Juan Carlos Aguillón
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

6.  Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium.

Authors:  Frances Humby; Michele Bombardieri; Antonio Manzo; Stephen Kelly; Mark C Blades; Bruce Kirkham; Jo Spencer; Costantino Pitzalis
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069

7.  Annexin 1 modulates monocyte-endothelial cell interaction in vitro and cell migration in vivo in the human SCID mouse transplantation model.

Authors:  Mauro Perretti; Francesca Ingegnoli; Samantha K Wheller; Mark C Blades; Egle Solito; Costantino Pitzalis
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

8.  Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide.

Authors:  Sarah E Wythe; Danielle DiCara; Taher E I Taher; Ciara M Finucane; Rita Jones; Michele Bombardieri; Y K Stella Man; Ahuva Nissim; Stephen J Mather; Yuti Chernajovsky; Costantino Pitzalis
Journal:  Ann Rheum Dis       Date:  2012-07-27       Impact factor: 19.103

9.  Macrophages in synovial inflammation.

Authors:  Aisling Kennedy; Ursula Fearon; Douglas J Veale; Catherine Godson
Journal:  Front Immunol       Date:  2011-10-10       Impact factor: 7.561

10.  Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis.

Authors:  Mathieu Ferrari; Shimobi C Onuoha; Liliane Fossati-Jimack; Alessandra Nerviani; Pedro L Alves; Sara Pagani; Cecilia Deantonio; Federico Colombo; Claudio Santoro; Daniele Sblattero; Costantino Pitzalis
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.